The only party not getting heartburn over GSK demerger is the lawyers | Nils Pratley
The Guardian - Pharmaceutical Industry
SEPTEMBER 20, 2022
The demerger of £24bn consumer healthcare group Haleon from its former parent, GlaxoSmithKline, is proving its truth in spades. Exhibit A is Haleon’s bill for separating, which has just leaped from £400m to £500m, largely because contracts were written in US dollars rather than (depreciating) sterling.
42 
Let's personalize your content